Pavaki Capital Management’s Altimmune ALT Stock Holding History

Pavaki Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-215,400	Closed	-$778K	–	157
2025 Q4	$778K	Buy	+215,400	New	+$939K	0.3%	52

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pavaki Capital Management's ALT Position: Q1 2026 in Review

Pavaki Capital Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 215,400 shares — an estimated $778K sold.

Pavaki Capital Management first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $778K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Pavaki Capital Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
Pavaki Capital Management sold 215,400 Altimmune shares in Q1 2026, an estimated $778K.
Pavaki Capital Management first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
Pavaki Capital Management's Altimmune position peaked at $778K in Q4 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Pavaki Capital Management's 13F filing for Q1 2026, filed 7 Aug 2026.